Suburban Research Associates

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Depression4 trials
• Alzheimer disease3 trials
• Autism2 trials
• Migraine2 trials
• Bipolar disorder1 trial
• Schizophrenia1 trial
• Tourette syndrome1 trial

Phase

• Phase 39 trials
• Phase 25 trials

Status

• Completed9 trials
• Active, not recruiting5 trials

Lead sponsor

• Biohaven Therapeutics Ltd.2 trials
• Ipsen2 trials
• MapLight Therapeutics2 trials
• Novo Nordisk A/S2 trials
• Annovis Bio Inc.1 trial
• and 5 more

Running trials

• Active, not recruiting

  A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

  NCT06709014· Phase 3· Annovis Bio Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

  NCT06047444· Phase 3· Ipsen· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

  NCT06047457· Phase 3· Ipsen· Source

• Active, not recruiting

  ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

  NCT05889273· Phase 2· MapLight Therapeutics· Source

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· COMPASS Pathways· Source

Closed trials

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

  NCT05615220· Phase 3· Emalex Biosciences Inc.· Source

• Completed

  ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

  NCT05081245· Phase 2· MapLight Therapeutics· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-55308942 in the Treatment of Bipolar Depression

  NCT05328297· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source